The Senate Finance Committee today held for Alex Azar, President Trump鈥檚 nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to the pharmaceutical industry and how he would tackle high drug prices. If confirmed, Azar said he would focus his efforts on addressing the high cost of drugs; making health care more affordable, available and 鈥渢ailored to what individuals want and need in their care鈥; harnessing 鈥渢he power of Medicare to shift the focus in our health care system from paying for procedures and sickness to paying for health and outcomes鈥; and tackling 鈥渢he scourge of the opioid epidemic.鈥 Tom Price, M.D., resigned as HHS secretary last September. Deputy Secretary Eric Hargan has been serving as acting secretary.

Related News Articles

Perspective
Public
One year ago, a nurse at Children鈥檚 Hospital Colorado went above and beyond in a way that a very young patient and her family will never forget. Kayla鈥
Headline
The AHA voiced support for the Securing Access to Care for Seniors in Critical Condition Act (H.R.1924), legislation that would provide reimbursement for long-鈥
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription鈥
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and鈥
Headline
The Centers for Medicare & Medicaid Services April 10 announced that it does not intend to approve new or extend existing requests for federal funds to鈥
Headline
The AHA April 11 commented on the Centers for Medicare & Medicaid Services鈥 2025 Marketplace Integrity and Affordability proposed rule. While the AHA鈥